{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:29:07Z","timestamp":1787232547265,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06541-6","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:26:18Z","timestamp":1781360778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC"],"prefix":"10.1007","volume":"152","author":[{"given":"Saikang","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"6541_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000541249\/4273883\/000541249.PDF","volume":"14","author":"X Bi","year":"2024","unstructured":"Bi X, Zhao H, Zhao H, Li G, Wang X, Chen B et al (2024) Consensus of Chinese expert on neoadjuvant and conversion therapies for hepatocellular carcinoma: 2023 update. Liver Cancer. 14:1\u201316. https:\/\/doi.org\/10.1159\/000541249\/4273883\/000541249.PDF","journal-title":"Liver Cancer."},{"issue":"3","key":"6541_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/CAAC.21834. PubMed PMID: 38572751","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"6541_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/CAAC.21338","volume":"66","author":"W Chen","year":"2015","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2015) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115\u2013132. https:\/\/doi.org\/10.3322\/CAAC.21338","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"6541_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/J.ANNONC.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS et al (2020) Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol 31(3):334\u2013351. https:\/\/doi.org\/10.1016\/J.ANNONC.2019.12.001","journal-title":"Ann Oncol"},{"issue":"2","key":"6541_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS et al (2023) Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol 8(2):169\u2013178. https:\/\/doi.org\/10.1016\/S2468-1253(22)00339-9. PubMed PMID: 36529152","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"6541_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3350\/CMH.2023.0099","volume":"29","author":"Y Cho","year":"2023","unstructured":"Cho Y, Kim BH, Park JW (2023) Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clin Mol Hepatol 29(2):252\u2013262. https:\/\/doi.org\/10.3350\/CMH.2023.0099","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"6541_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1159\/000537966","volume":"13","author":"RS Finn","year":"2024","unstructured":"Finn RS, Kudo M, Barnes G, Meyer T, Boisserie F, Abdrashitov R et al (2024) Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study. Liver Cancer. 13(5):548. https:\/\/doi.org\/10.1159\/000537966. PubMed PMID: 39435268","journal-title":"Liver Cancer."},{"issue":"12","key":"6541_CR8","doi-asserted-by":"publisher","first-page":"8669","DOI":"10.1007\/S00330-023-09754-2","volume":"33","author":"ZC Jin","year":"2023","unstructured":"Jin ZC, Zhong BY, Chen JJ, Zhu HD, Sun JH, Yin GW et al (2023) Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study. Eur Radiol 33(12):8669\u20138681. https:\/\/doi.org\/10.1007\/S00330-023-09754-2. PubMed PMID: 37368105","journal-title":"Eur Radiol"},{"issue":"10126","key":"6541_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1. PubMed PMID: 29433850","journal-title":"Lancet"},{"issue":"10474","key":"6541_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J et al (2025) Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 405(10474):203\u2013215. https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3. PubMed PMID: 39798578","journal-title":"Lancet"},{"issue":"1","key":"6541_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/HEP.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 64(1):106\u2013116. https:\/\/doi.org\/10.1002\/HEP.28453. PubMed PMID: 26765068","journal-title":"Hepatology"},{"key":"6541_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPS.2023.106549","volume":"189","author":"J Li","year":"2023","unstructured":"Li J, Zhang L, Tao Y, Sun Z, Ge Y, Hu S (2023) Combination of transcatheter arterial chemoembolization and anti-PD-L1 liposomes therapy suppressed hepatocellular carcinoma progression in mice. Eur J Pharm Sci 189:106549. https:\/\/doi.org\/10.1016\/J.EJPS.2023.106549. PubMed PMID: 37524271","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"6541_CR13","doi-asserted-by":"publisher","first-page":"14398","DOI":"10.3892\/OL.2024.14398","volume":"27","author":"S Li","year":"2024","unstructured":"Li S, Zhang Z, Wang Z, Wang K, Sui M, Liu D et al (2024) Lenvatinib-based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Oncol Lett 27(6):14398. https:\/\/doi.org\/10.3892\/OL.2024.14398. PubMed PMID: 38659422","journal-title":"Oncol Lett"},{"issue":"4","key":"6541_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/AGT2.552","volume":"5","author":"X Liang","year":"2024","unstructured":"Liang X, Liu H, Chen H, Peng X, Li Z, Teng M et al (2024) Rhein-based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization. Aggregate 5(4):e552. https:\/\/doi.org\/10.1002\/AGT2.552","journal-title":"Aggregate"},{"issue":"1","key":"6541_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1515\/ONCOLOGIE-2023-0360","volume":"26","author":"X Lin","year":"2023","unstructured":"Lin X, Tian C, Pan F, Wang R (2023) A novel immune-associated prognostic signature based on the immune cell infiltration analysis for hepatocellular carcinoma. Oncologie 26(1):91\u2013103. https:\/\/doi.org\/10.1515\/ONCOLOGIE-2023-0360","journal-title":"Oncologie"},{"issue":"1","key":"6541_CR16","doi-asserted-by":"publisher","first-page":"21728","DOI":"10.1038\/S41598-024-72907-W","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Bai Y, Liu X, Zhou B, Sun P, Wang Y et al (2024) Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma. Sci Rep 14(1):21728. https:\/\/doi.org\/10.1038\/S41598-024-72907-W. PubMed PMID: 39289512","journal-title":"Sci Rep"},{"issue":"5","key":"6541_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/S41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T et al (2021) Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18(5):293\u2013313. https:\/\/doi.org\/10.1038\/S41575-020-00395-0. PubMed PMID: 33510460","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"6541_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3350\/CMH.2022.0294","volume":"28","author":"JW Park","year":"2022","unstructured":"Park JW (2022) 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 28(4):583\u2013705. https:\/\/doi.org\/10.3350\/CMH.2022.0294. PubMed PMID: 36263666","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"6541_CR19","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-24-0177","volume":"30","author":"DJ Pinato","year":"2024","unstructured":"Pinato DJ, D\u2019Alessio A, Fulgenzi CAM, Schlaak AE, Celsa C, Killmer S et al (2024) Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study. Clin Cancer Res 30(11):2433\u20132443. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0177. PubMed PMID: 38578610","journal-title":"Clin Cancer Res"},{"issue":"12","key":"6541_CR20","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/JAMAONCOL.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z et al (2023) Tislelizumab versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol 9(12):1651\u20131659. https:\/\/doi.org\/10.1001\/JAMAONCOL.2023.4003. PubMed PMID: 37796513","journal-title":"JAMA Oncol"},{"issue":"3","key":"6541_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/J.JHEP.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1 et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76(3):681\u2013693. https:\/\/doi.org\/10.1016\/J.JHEP.2021.11.018","journal-title":"J Hepatol"},{"issue":"10474","key":"6541_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL et al (2025) Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet 405(10474):216\u2013232. https:\/\/doi.org\/10.1016\/S0140-6736(24)02551-0. PubMed PMID: 39798579","journal-title":"The Lancet"},{"issue":"1","key":"6541_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/S00534-010-0314-0","volume":"18","author":"J Shi","year":"2011","unstructured":"Shi J, Lai ECH, Li N, Guo WX, Xue J, Lau WY et al (2011) A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci 18(1):74\u201380. https:\/\/doi.org\/10.1007\/S00534-010-0314-0. PubMed PMID: 20686792","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"4","key":"6541_CR24","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/HEP.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A et al (2020) Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71(4):1247\u20131261. https:\/\/doi.org\/10.1002\/HEP.30889. PubMed PMID: 31378984","journal-title":"Hepatology"},{"key":"6541_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2024.105436","volume":"109","author":"L Song","year":"2024","unstructured":"Song L, Zhu C, Shi Q, Xia Y, Liang X, Qin W et al (2024) Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression. EBioMedicine 109:105436. https:\/\/doi.org\/10.1016\/J.EBIOM.2024.105436. PubMed PMID: 39476535","journal-title":"EBioMedicine"},{"issue":"2","key":"6541_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.21037\/HBSN-21-328","volume":"11","author":"HC Sun","year":"2022","unstructured":"Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W et al (2022) Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 11(2):227\u2013252. https:\/\/doi.org\/10.21037\/HBSN-21-328. PubMed PMID: 35464283","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"3","key":"6541_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2020) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/CAAC.21660","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6541_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/J.JHEP.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S et al (2023) TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol 79(1):126\u2013140. https:\/\/doi.org\/10.1016\/J.JHEP.2023.02.032. PubMed PMID: 36889359","journal-title":"J Hepatol"},{"issue":"8","key":"6541_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S2468-1253(21)00110-2","volume":"6","author":"A Vogel","year":"2021","unstructured":"Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T et al (2021) Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 6(8):649\u2013658. https:\/\/doi.org\/10.1016\/S2468-1253(21)00110-2. PubMed PMID: 34087115","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"6541_CR30","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S1470-2045(20)30073-5","volume":"21","author":"W Wei","year":"2020","unstructured":"Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R et al (2020) Cancer registration in China and its role in cancer prevention and control. Lancet Oncol 21(7):e342\u2013e349. https:\/\/doi.org\/10.1016\/S1470-2045(20)30073-5","journal-title":"Lancet Oncol"},{"key":"6541_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.783236","volume":"12","author":"R Xing","year":"2021","unstructured":"Xing R, Gao J, Cui Q, Wang Q (2021) Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front Immunol 12:783236. https:\/\/doi.org\/10.3389\/FIMMU.2021.783236. PubMed PMID: 34899747","journal-title":"Front Immunol"},{"issue":"1","key":"6541_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/S12916-024-03356-5","volume":"22","author":"L Xu","year":"2024","unstructured":"Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H et al (2024) Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. BMC Med 22(1):172. https:\/\/doi.org\/10.1186\/S12916-024-03356-5. PubMed PMID: 38650037","journal-title":"BMC Med"},{"issue":"3","key":"6541_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/J.JNCC.2023.02.001","volume":"3","author":"J Yang","year":"2023","unstructured":"Yang J, Yang Z, Zeng X, Yu S, Gao L, Jiang Y et al (2023a) Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis. J Natl Cancer Cent 3(3):175\u2013185. https:\/\/doi.org\/10.1016\/J.JNCC.2023.02.001","journal-title":"J Natl Cancer Cent"},{"issue":"4","key":"6541_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/S41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W et al (2023b) Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 20(4):203\u2013222. https:\/\/doi.org\/10.1038\/S41575-022-00704-9. PubMed PMID: 36369487","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"6541_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/J.CCELL.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R et al (2024) Precision treatment in advanced hepatocellular carcinoma. Cancer Cell 42(2):180\u2013197. https:\/\/doi.org\/10.1016\/J.CCELL.2024.01.007. PubMed PMID: 38350421","journal-title":"Cancer Cell"},{"issue":"5","key":"6541_CR36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y et al (2023) TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg 109(5):1222\u20131230. https:\/\/doi.org\/10.1097\/JS9.0000000000000256. PubMed PMID: 37026861","journal-title":"Int J Surg"},{"issue":"3","key":"6541_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/J.JNCC.2024.06.005","volume":"4","author":"H Zeng","year":"2019","unstructured":"Zeng H, Zheng R, Sun K, Zhou M, Wang S, Li L et al (2019) Cancer survival statistics in China 2019-2021: a multicenter, population-based study. J Natl Cancer Cent 4(3):203\u2013213. https:\/\/doi.org\/10.1016\/J.JNCC.2024.06.005","journal-title":"J Natl Cancer Cent"},{"key":"6541_CR38","doi-asserted-by":"publisher","first-page":"1449963","DOI":"10.3389\/FIMMU.2024.1449663\/PDF","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Wen S, Xue YQ, Dang Z, Nan ZY, Wang D et al (2024) Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study. Front Immunol 15:1449963. https:\/\/doi.org\/10.3389\/FIMMU.2024.1449663\/PDF. PubMed PMID: 39411718","journal-title":"Front Immunol"},{"issue":"10204","key":"6541_CR39","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W et al (2019) Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 394(10204):1145\u20131158. https:\/\/doi.org\/10.1016\/S0140-6736(19)30427-1. PubMed PMID: 31248666","journal-title":"Lancet"},{"issue":"5","key":"6541_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W et al (2023) Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition). Liver Cancer. 12(5):405\u2013444. https:\/\/doi.org\/10.1159\/000530495. PubMed PMID: 37901768","journal-title":"Liver Cancer."},{"issue":"1","key":"6541_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/S41392-022-01235-0","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY et al (2023) Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther 8(1):58. https:\/\/doi.org\/10.1038\/S41392-022-01235-0. PubMed PMID: 36750721","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"6541_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1200\/JCO-25-01796","volume":"44","author":"HD Zhu","year":"2026","unstructured":"Zhu HD, Fan WJ, Zhao C, Wang S, Li YL, Jin ZC et al (2026) Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005\/CARES-005): A Randomized Phase II Trial. J Clin Oncol 44(11):959\u2013969. https:\/\/doi.org\/10.1200\/JCO-25-01796. PubMed PMID: 41734362","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06541-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:03:26Z","timestamp":1787231006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06541-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6541"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06541-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Saikang Tang, Xue Yan, Tao Gong, Weihua Zhi, Yingming Gao and Yue Han declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study adhered to the ethical standards of the responsible committee on human experimentation (both institutional and national) and the Helsinki Declaration of 1975, as revised in 2008. The study received ethics approval from the Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences (Approval Number: NCC5598), which granted a waiver for individual informed consent given the anonymized nature of data and minimal risk to participants.","order":2,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"163"}}